PeptidePedia The community reference

Contributions of COA_Colwyn

User contributions·87 logged edits·page 1 of 1

Contributions by COA_Colwyn, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 13,744 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Asymchem Laboratories 17,162 +2 clarify that no manufacturing or marketing authorisation is claimed or established
  2. 14:05, 26 Jul 2026 (diff | hist) Talk:Thermo Fisher Scientific (China) 1,170 +134 /* Retained certificates: continuity, or a stability claim? */ reply
  3. 10:15, 26 Jul 2026 (diff | hist) Talk:Thermo Fisher Scientific (China) 537 +432 /* Retained certificates: continuity, or a stability claim? */ new section
  4. 11:47, 24 Jul 2026 (diff | hist) Thermo Fisher Scientific (China) 2,552 ±0 rm the adjective — an organisation article describes, it does not praise
  5. 11:20, 21 Jul 2026 (diff | hist) Talk:Asymchem Laboratories 1,170 +276 /* Four reports against one lot: what does that actually establish? */ reply
  6. 13:01, 20 Jul 2026 (diff | hist) Exenatide 5,754 ±0 add the year of first marketing authorisation, with the regulator named
  7. 10:15, 20 Jul 2026 (diff | hist) Talk:Asymchem Laboratories 537 +345 /* Four reports against one lot: what does that actually establish? */ new section
  8. 10:20, 22 Jun 2026 (diff | hist) Talk:Cost per milligram 537 +163 /* Documentation is not in the price */ new section
  9. 13:20, 20 Jun 2026 (diff | hist) Talk:Amylin receptor agonist 885 +186 /* Method-coverage sentence */ reply
  10. 05:53, 20 Jun 2026 (diff | hist) WuXi TIDES 16,434 ±0 state the city and province of the registered address
  11. 14:40, 16 Jun 2026 (diff | hist) Talk:Solid-phase peptide synthesis 885 +115 /* Process detail versus quality attributes */ reply
  12. 13:55, 12 Jun 2026 (diff | hist) Talk:Drug master file 748 +66 /* Same shape as other claims */ reply
  13. 13:55, 9 Jun 2026 (diff | hist) Talk:Retention time 748 +101 /* Within-system value */ reply
  14. 10:25, 9 Jun 2026 (diff | hist) Talk:Purity claim inflation 674 +182 /* Checkability as the criterion */ new section
  15. 09:40, 8 Jun 2026 (diff | hist) Injection site rotation 4,872 ±0 m the vial strength in the example was inconsistent between two paragraphs
  16. 15:20, 5 Jun 2026 (diff | hist) Talk:Janoshik Analytical 885 +191 /* Should content determination be described as an option? */ reply
  17. 11:47, 31 May 2026 (diff | hist) Counterfeit peptide 5,488 ±0 m label the community tally as self-reported at this point of use as well
  18. 12:50, 30 May 2026 (diff | hist) Talk:CagriSema 885 +168 /* Two powders in proportion */ reply
  19. 13:55, 29 May 2026 (diff | hist) Talk:Cagrilintide 748 +63 /* Aggregation and method coverage */ reply
  20. 13:55, 27 May 2026 (diff | hist) Talk:Good manufacturing practice 748 +132 /* The uncomfortable inference */ reply
  21. 10:20, 26 May 2026 (diff | hist) Talk:Hypoglycaemia 537 +178 /* Unknown exposure */ new section
  22. 23:55, 7 May 2026 (diff | hist) Chinese Peptide Company 15,513 ±0 add the research-use-only statement to the lead rather than only the footer
  23. 13:11, 28 Apr 2026 (diff | hist) Shanghai ERP Biotechnology 14,637 ±0 add the standing talk-page note link to the banner
  24. 14:50, 30 Mar 2026 (diff | hist) Talk:Semaglutide 748 +262 /* How much detail on research-chemical material? */ reply
  25. 10:05, 17 Mar 2026 (diff | hist) Talk:USP General Chapter 85 400 +174 /* Tested by versus meets the limit */ new section
  26. 20:20, 16 Mar 2026 (diff | hist) Shenzhen Hybio Pharmaceutical 17,496 +1,144 add the how-to-request-a-batch-record sentence to §Ordering and availability
  27. 13:50, 16 Mar 2026 (diff | hist) Talk:Batch number 611 +102 /* Date-ordering check */ reply
  28. 05:51, 12 Mar 2026 (diff | hist) Sigma-Aldrich (Shanghai) Trading 18,641 ±0 add the storage and handling guidance the organisation publishes
  29. 11:37, 6 Mar 2026 (diff | hist) Talk:Sigma-Aldrich (Shanghai) Trading 959 +257 /* Trading company or synthesis house, and whether the article should say */ reply
  30. 20:48, 5 Mar 2026 (diff | hist) Sangon Biotech 14,764 ±0 m add the storage and handling guidance the organisation publishes
  31. 16:17, 5 Mar 2026 (diff | hist) Qingdao Sigma Chemical 15,455 ±0 correct the other-designations row — those are trading variants, not subsidiaries
  32. 14:00, 2 Mar 2026 (diff | hist) Talk:Limit of detection 611 +158 /* The inverted reading */ reply
  33. 10:17, 22 Feb 2026 (diff | hist) Hunan Aslsen Technology 15,492 ±0 ce, tighten prose
  34. 13:00, 18 Feb 2026 (diff | hist) Talk:Residual solvent 611 +161 /* Targeted determination */ reply
  35. 10:58, 14 Feb 2026 (diff | hist) Talk:SinoPep 1,170 +154 /* Whether the counter-ion figure belongs in the lead */ reply
  36. 10:52, 13 Feb 2026 (diff | hist) Talk:PolyPeptide Group (Hangzhou) 959 +240 /* A printed trace and a filled vial are not the same object */ reply
  37. 09:40, 11 Feb 2026 (diff | hist) Talk:SinoPep 537 +346 /* Whether the counter-ion figure belongs in the lead */ new section
  38. 07:47, 19 Jan 2026 (diff | hist) Certificate of analysis 10,014 ±0 serial comma per PP:MOS
  39. 14:32, 14 Jan 2026 (diff | hist) Shanghai Sigma-Audley New Material Technology 15,359 ±0 expand §Regulatory position and legal status
  40. 09:30, 8 Jan 2026 (diff | hist) Talk:Third-party testing 400 +205 /* The three questions */ new section
  41. 16:00, 1 Jan 2026 (diff | hist) Shanghai ERP Biotechnology 12,013 +1,773 add the note that self-published material is usable only for what it states about itself
  42. 12:03, 1 Jan 2026 (diff | hist) Certificate of analysis 10,014 ±0 state what the certificate actually carries, field by field
  43. 23:18, 8 Nov 2025 (diff | hist) Shanghai ERP Biotechnology 8,800 +451 add the see-also to the certificate-of-analysis article
  44. 13:40, 2 Oct 2025 (diff | hist) Talk:AmbioPharm 611 +374 /* Notability, and what a long registry record does not establish */ reply
  45. 20:30, 1 Oct 2025 (diff | hist) GenScript Peptides 7,116 +767 rm the price; supplier articles carry no price per PP:VN
  46. 18:15, 20 Sep 2025 (diff | hist) PolyPeptide Group (Hangzhou) 6,060 +2,396 add the research-use-only statement to the lead rather than only the footer
  47. 06:55, 19 Sep 2025 (diff | hist) SinoPep 9,488 +251 m attribute the capability claim to the organisation's own material
  48. 09:22, 18 Sep 2025 (diff | hist) Talk:WuXi TIDES 959 +254 /* Where should the ordering facts sit? */ reply
  49. 10:40, 5 Sep 2025 (diff | hist) Talk:GenScript Peptides 822 +303 /* Notability, and what a long registry record does not establish */ reply
  50. 17:28, 3 Sep 2025 (diff | hist) Certificate of analysis 9,814 ±0 m clarify that a QR code on a certificate proves issuance, not content
  51. 12:08, 3 Sep 2025 (diff | hist) PolyPeptide Group (Hangzhou) 2,650 +2,650 N create organisation article per PP:VN
  52. 13:41, 2 Sep 2025 (diff | hist) Talk:PolyPeptide Group (Hangzhou) 611 +348 /* Notability, and what a printed chromatogram does and does not establish */ reply
  53. 10:05, 14 Aug 2025 (diff | hist) Talk:Shenzhen Hybio Pharmaceutical 822 +320 /* Notability, and what a long registry record does not establish */ reply
  54. 05:52, 21 Jul 2025 (diff | hist) Shanghai Wibson Biotechnology 9,082 +392 add the minimum order quantity for custom synthesis
  55. 09:35, 24 Jun 2025 (diff | hist) SinoPep 2,977 +38 add category for suppliers in China
  56. 10:18, 13 Jun 2025 (diff | hist) Talk:Shanghai Sigma-Audley New Material Technology 1,170 +85 /* Packaging consistency: observation or compliment? */ reply
  57. 09:40, 11 Jun 2025 (diff | hist) Talk:Shanghai Sigma-Audley New Material Technology 537 +366 /* Packaging consistency: observation or compliment? */ new section
  58. 08:47, 11 Jun 2025 (diff | hist) Talk:SinoPep 822 +278 /* Notability, and whether a documentary distinction is a notable one */ reply
  59. 10:12, 4 Jun 2025 (diff | hist) Talk:Sangon Biotech 1,170 +197 /* Comparing documentation within one organisation */ reply
  60. 09:50, 2 Jun 2025 (diff | hist) Talk:Sangon Biotech 537 +291 /* Comparing documentation within one organisation */ new section
  61. 04:27, 27 Apr 2025 (diff | hist) Qingdao Sigma Chemical 10,623 +321 rm the adjective — an organisation article describes, it does not praise
  62. 14:38, 21 Apr 2025 (diff | hist) Talk:Sigma-Aldrich (Shanghai) Trading 611 +383 /* A distributor that does not claim manufacture, and what the article may infer from that */ reply
  63. 21:52, 3 Apr 2025 (diff | hist) Xi'an Mokemei Biotechnology 2,374 ±0 rm a duplicated category
  64. 03:51, 26 Mar 2025 (diff | hist) High-performance liquid chromatography 6,011 +647 m add the ionisation mode to the mass-spectrometry description
  65. 22:54, 19 Mar 2025 (diff | hist) Janoshik Analytical 4,126 ±0 add the second-opinion point: two services, one lot, is a stronger record
  66. 09:00, 19 Mar 2025 (diff | hist) Xi'an Mokemei Biotechnology 2,185 +2,185 N start organisation article — registry facts and product scope only
  67. 16:50, 15 Mar 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 7,523 +507 add the registered legal name exactly as it appears in the registry record
  68. 23:57, 11 Mar 2025 (diff | hist) GL Biochem (Shanghai) 11,744 +949 rm the comparison with another supplier; there is no common basis for it
  69. 04:05, 21 Feb 2025 (diff | hist) TRIUMPH trial programme 3,495 ±0 typo
  70. 05:01, 8 Feb 2025 (diff | hist) Guangzhou JEEP Biotechnology 8,821 +494 expand the product-scope row in the infobox
  71. 01:35, 21 Dec 2024 (diff | hist) Missed dose 3,355 ±0 m the vial strength in the example was inconsistent between two paragraphs
  72. 10:39, 1 Dec 2024 (diff | hist) Proglucagon 4,138 +673 add see also to the sister hormone
  73. 21:24, 27 Nov 2024 (diff | hist) Batch number 3,013 +31 state the date range the submitted set covers
  74. 03:34, 25 Nov 2024 (diff | hist) Amino acid analysis 2,043 ±0 m correct the integration description — valley-to-valley, not drop-line
  75. 01:33, 22 Nov 2024 (diff | hist) ChinaPeptides 3,956 +1,017 expand §Distribution and dispatch
  76. 20:40, 7 Nov 2024 (diff | hist) PeptideMeter 2,876 +116 m state the date range the submitted set covers
  77. 02:41, 7 Nov 2024 (diff | hist) Qingdao Sigma Chemical 5,282 +804 convert the product range to a table so the documentation column lines up
  78. 19:37, 13 Oct 2024 (diff | hist) Glucagon-like peptide-1 7,399 +178 add the species in which the knockout work was done
  79. 15:26, 11 Oct 2024 (diff | hist) Mass spectrometry 3,840 +812 add the plate-count expression and define its terms
  80. 11:22, 4 Sep 2024 (diff | hist) Talk:Certificate of analysis 1,033 +70 /* Is "a claim by its issuer" too strong? */ reply
  81. 20:01, 2 Sep 2024 (diff | hist) Batch number 1,993 ±0 alphabetise the see-also list
  82. 10:14, 2 Sep 2024 (diff | hist) Talk:Certificate of analysis 400 +180 /* Is "a claim by its issuer" too strong? */ new section
  83. 22:36, 19 Aug 2024 (diff | hist) Certificate of analysis 1,858 +1,858 N create article — testing stub
  84. 21:16, 17 Aug 2024 (diff | hist) Cagrilintide 1,293 ±0 m give the INN alongside the trade name at first mention
  85. 07:35, 16 Jul 2024 (diff | hist) Wuhan Wansheng Biotechnology 2,899 +38 add the registered legal name exactly as it appears in the registry record
  86. 23:55, 10 Jul 2024 (diff | hist) Guangzhou JEEP Biotechnology 2,715 +2,715 N create organisation article per PP:VN
  87. 06:11, 21 Jun 2024 (diff | hist) Reconstitution of lyophilised peptides 1,487 +1,487 N new article: dosing and handling, expansion welcome